In order to determine which patients may respond best to checkpoint inhibition we retrospectively analyzed immune cell infiltration and PD-L1 status in a cohort of melanoma treated with CTLA-4 and/or anti-PD-1 inhibitors. The gene discussed is CTLA4; the disease is melanoma.